Clarithromycin
Check Drug InteractionsCheck known drug interactions.
Check Drug InteractionsClarithromycin Prescribing Information
Contraindications
Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibacterial drugs [see Warnings and Precautions (5.1)] .Concomitant administration of clarithromycin with cisapride and pimozide is contraindicated [see Drug Interactions (7)] .There have been postmarketing reports of drug interactions when clarithromycin is co-administered with cisapride or pimozide, resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes ) most likely due to inhibition of metabolism of these drugs by clarithromycin. Fatalities have been reported.Clarithromycin is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of clarithromycin. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment. Concomitant administration of clarithromycin with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions (5.4)and Drug Interactions (7)] .Concomitant administration of clarithromycin with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) is contraindicated, due to the increased risk of myopathy, including rhabdomyolysis [see Warnings and Precautions (5.4)and Drug Interactions (7)] .Concomitant administration of clarithromycin and ergotamine or dihydroergotamine is contraindicated [see Drug Interactions (7)] .Concomitant administration of clarithromycin and lurasidone is contraindicated since it may result in an increase in lurasidone exposure and the potential for serious adverse reactions [see Drug Interactions (7)] .For information about contraindications of other drugs indicated in combination with clarithromycin, refer to their full prescribing information (contraindications section). | 05/2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug InteractionsCo-administration of clarithromycin is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug. Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin.
Co-administration of clarithromycin can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy. (4, 5.2, 5.4, 7) | 05/2023 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin and other antibacterial drugs, clarithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Decrease the dose of clarithromycin by 50% when co-administered with atazanavir
[see Drug Interactions
]
. Dosage adjustments for other drugs when co-administered with clarithromycin may be recommended due to drug interactionsCo-administration of clarithromycin is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.
Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin.
Drugs That Are Affected By Clarithromycin | |||||
Drug(s) with Pharmacokinetics Affected by Clarithromycin | Recommendation | Comments | |||
| Antiarrhythmics: | |||||
| Disopyramide Quinidine Dofetilide Amiodarone Sotalol Procainamide | Not Recommended | Disopyramide, Quinidine: There have been postmarketing reports oftorsades de pointes occurring with concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QTc prolongation during coadministration of clarithromycin with these drugs[see Warnings and Precautions ( 5.2 )] .Serum concentrations of these medications should also be monitored. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with disopyramide and quinidine. There have been postmarketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore, blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide. | |||
| Digoxin | Use With Caution | Digoxin: Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are co-administered, inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range. | |||
| Oral Anticoagulants: | |||||
| Warfarin | Use With Caution | Oral anticoagulants: Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously[see Warnings and Precautions (5.4)] . | |||
| Antiepileptics: | |||||
| Carbamazepine | Use With Caution | Carbamazepine: Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered. Increased serum concentrations of carbamazepine were observed in clinical trials with clarithromycin. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with carbamazepine. | |||
| Antifungals: | |||||
| Itraconazole | Use With Caution | Itraconazole: Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly (see also Itraconazole under “Drugs That Affect Clarithromycin”in the table below). Clarithromycin may increase the plasma concentrations of itraconazole. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions. | |||
| Fluconazole | No Dose Adjustment | Fluconazole: [see Pharmacokinetics (12.3)] | |||
| Anti-Gout Agents: | |||||
| Colchicine (in patients with renal or hepatic impairment) | Contraindicated | Colchicine: Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. The dose of colchicine should be reduced when co-administered with clarithromycin in patients with normal renal and hepatic function[see Contraindications (4.4) and Warnings and Precautions (5.4)] . | |||
| Colchicine (in patients with normal renal and hepatic function) | Use With Caution | ||||
| Antipsychotics: | |||||
| Pimozide | Contraindicated | Pimozide: [See Contraindications (4.2)] | |||
| Quetiapine | Quetiapine: Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. Co-administration with clarithromycin could result in increased quetiapine exposure and possible quetiapine related toxicities. There have been postmarketing reports of somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation during concomitant administration. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as clarithromycin. | ||||
| Lurasidone | Lurasidone: [See Contraindications (4.7)] | ||||
| Antispasmodics: | |||||
| Tolterodine (patients deficient in CYP2D6 activity) | Use With Caution | Tolterodine: The primary route of metabolism for tolterodine is via CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with clarithromycin. | |||
| Antivirals: | |||||
| Atazanavir | Use With Caution | Atazanavir: Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction (see Atazanavir under “Drugs That Affect Clarithromycin”in the table below)[see Pharmacokinetics (12.3)] . | |||
| Saquinavir (in patients with decreased renal function) | Saquinavir: Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction (see Saquinavir under “Drugs That Affect Clarithromycin”in the table below)[see Pharmacokinetics (12.3)] . | ||||
| Ritonavir Etravirine | Ritonavir, Etravirine: (see Ritonavir and Etravirine under “Drugs That Affect Clarithromycin”in the table below)[see Pharmacokinetics (12.3)] . | ||||
| Maraviroc | Maraviroc: Clarithromycin may result in increases in maraviroc exposures by inhibition of CYP3A metabolism. See Selzentry®prescribing information for dose recommendation when given with strong CYP3A inhibitors such as clarithromycin. | ||||
| Boceprevir (in patients with normal renal function) Didanosine | No Dose Adjustment | Boceprevir: Both clarithromycin and boceprevir are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when co-administered. No dose adjustments are necessary for patients with normal renal function (see Victrelis®prescribing information). | |||
| Zidovudine | Zidovudine: Simultaneous oral administration of clarithromycin immediate-release tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Administration of clarithromycin and zidovudine should be separated by at least two hours[see Pharmacokinetics (12.3)] .The impact of co-administration of clarithromycin extended-release tablets or granules and zidovudine has not been evaluated. | ||||
| Calcium Channel Blockers: | |||||
| Verapamil | Use With Caution | Verapamil: Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil,[see Warnings and Precautions (5.4)] . | |||
| Amlodipine Diltiazem | Amlodipine, Diltiazem: [See Warnings and Precautions (5.4)] | ||||
| Nifedipine | Nifedipine: Nifedipine is a substrate for CYP3A. Clarithromycin and other macrolides are known to inhibit CYP3A. There is potential of CYP3A-mediated interaction between nifedipine and clarithromycin. Hypotension and peripheral edema were observed when clarithromycin was taken concomitantly with nifedipine[see Warnings and Precautions (5.4)] . | ||||
| Ergot Alkaloids: | |||||
| Ergotamine Dihydroergotamine | Contraindicated | Ergotamine, Dihydroergotamine: Postmarketing reports indicate that coadministration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system[see Contraindications (4.6)] . | |||
| Gastroprokinetic Agents: | |||||
| Cisapride | Contraindicated | Cisapride: [See Contraindications (4.2)] | |||
| Lipid-lowering agents: | |||||
| Lomitapide Lovastatin Simvastatin | Contraindicated | Lomitapide, Lovastatin, Simvastatin: Clarithromycin may increase the exposure of these drugs by inhibition of CYP3A metabolism, thereby increasing the risk of toxicities from these drugs [See Contraindications (4.5) and Warnings and Precautions (5.4)] Atorvastatin, Pravastatin, Fluvastatin: [See Warnings and Precautions (5.4)] | |||
| Atorvastatin Pravastatin | Use With Caution | ||||
| Fluvastatin | No Dose Adjustment | ||||
| Hypoglycemic Agents: | |||||
| Nateglinide Pioglitazone Repaglinide Rosiglitazone | Use With Caution | Nateglinide, Pioglitazone, Repaglinide, Rosiglitazone: [See Warnings and Precautions (5.4) and Adverse Reactions (6.2)] | |||
| Insulin | Insulin: [See Warnings and Precautions (5.4)and Adverse Reactions (6.2)] | ||||
| Immunosuppressants: | |||||
| Cyclosporine | Use With Caution | Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. | |||
| Tacrolimus | Tacrolimus: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with tacrolimus. | ||||
| Phosphodiesterase inhibitors: | |||||
| Sildenafil Tadalafil Vardenafil | Use With Caution | Sildenafil, Tadalafil, Vardenafil: Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors. Co-administration of these phosphodiesterase inhibitors with clarithromycin is not recommended. Increased systemic exposure of these drugs may occur with clarithromycin; reduction of dosage for phosphodiesterase inhibitors should be considered (see their respective prescribing information). | |||
| Proton Pump Inhibitors: | |||||
| Omeprazole | No Dose Adjustment | Omeprazole: The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin as a result of increased omeprazole exposures[see Pharmacokinetics (12.3)] (see also Omeprazole under “Drugs That Affect Clarithromycin”in the table below). | |||
| Xanthine Derivatives: | |||||
| Theophylline | Use With Caution | Theophylline: Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations[see Pharmacokinetics (12.3)] . Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range. | |||
| Triazolobenzodiazepines and Other Related Benzodiazepines: | |||||
| Midazolam | Use With Caution | Midazolam: When oral midazolam is co-administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated[see Warnings and Precautions (5.4) and Pharmacokinetics (12.3)] . | |||
| Alprazolam Triazolam | Triazolam, Alprazolam: Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is co-administered with clarithromycin. There have been postmarketing reports of drug interactions and central nervous system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.In postmarketing experience, erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines. | ||||
| Temazepam Nitrazepam Lorazepam | No Dose Adjustment | Temazepam, Nitrazepam, Lorazepam: For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely. | |||
| Cytochrome P450 Inducers: | |||||
| Rifabutin | Use With Caution | Rifabutin: Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis (see Rifabutin under “Drugs That Affect Clarithromycin”in the table below). | |||
| Other Drugs Metabolized by CYP3A: | |||||
| Alfentanil Bromocriptine Cilostazol Methylprednisole Vinblastine Phenobarbital St. John’s Wort | Use With Caution | There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with alfentanil, methylprednisolone, cilostazol, bromocriptine, vinblastine, phenobarbital, and St. John’s Wort. | |||
| Other Drugs Metabolized by CYP450 Isoforms Other than CYP3A: | |||||
| Hexobarbital Phenytoin Valproate | Use With Caution | There have been postmarketing reports of interactions of clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate. | |||
Drugs that Affect Clarithromycin | |||||
Drug(s) that Affect the Pharmacokinetics of Clarithromycin | Recommendation | Comments | |||
| Antifungals: | |||||
| Itraconazole | Use With Caution | Itraconazole: Itraconazole may increase the plasma concentrations of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions (see also Itraconazole under “Drugs That Are Affected By Clarithromycin”in the table above). | |||
| Antivirals: | |||||
| Atazanavir | Use With Caution | Atazanavir: When clarithromycin is co-administered with atazanavir, the dose of clarithromycin should be decreased by 50%[see Clinical Pharmacology (12.3)] .Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to Mycobacterium avium complex. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors. | |||
| Ritonavir (in patients with decreased renal function) | Ritonavir: Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due toMycobacterium avium [see Pharmacokinetics (12.3)] .Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors. | ||||
| Saquinavir (in patients with decreased renal function) | Saquinavir: When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to ritonavir above)[see Pharmacokinetics (12.3)] . | ||||
| Etravirine | Etravirine: Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity againstMycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC. | ||||
| Saquinavir (in patients with normal renal function) | No Dose Adjustment | ||||
| Ritonavir (in patients with normal renal function) | |||||
| Proton Pump Inhibitors: | |||||
| Omeprazole | Use With Caution | Omeprazole: Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole[see Pharmacokinetics (12.3)] . | |||
| Miscellaneous Cytochrome P450 Inducers: | |||||
| Efavirenz Nevirapine Rifampicin Rifabutin Rifapentine | Use With Caution | Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers. Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with rifabutin (see Rifabutin under “Drugs That Are Affected By Clarithromycin”in the table above). | |||
Co-administration of clarithromycin can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy. (4, 5.2, 5.4, 7)
[see Drug Interactions
]
.Co-administration of clarithromycin is known to inhibit CYP3A, and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.
Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g., carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Adjust dosage when appropriate and monitor serum concentrations of drugs primarily metabolized by CYP3A closely in patients concurrently receiving clarithromycin.
Drugs That Are Affected By Clarithromycin | |||||
Drug(s) with Pharmacokinetics Affected by Clarithromycin | Recommendation | Comments | |||
| Antiarrhythmics: | |||||
| Disopyramide Quinidine Dofetilide Amiodarone Sotalol Procainamide | Not Recommended | Disopyramide, Quinidine: There have been postmarketing reports oftorsades de pointes occurring with concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QTc prolongation during coadministration of clarithromycin with these drugs[see Warnings and Precautions ( 5.2 )] .Serum concentrations of these medications should also be monitored. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with disopyramide and quinidine. There have been postmarketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore, blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide. | |||
| Digoxin | Use With Caution | Digoxin: Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are co-administered, inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range. | |||
| Oral Anticoagulants: | |||||
| Warfarin | Use With Caution | Oral anticoagulants: Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously[see Warnings and Precautions (5.4)] . | |||
| Antiepileptics: | |||||
| Carbamazepine | Use With Caution | Carbamazepine: Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered. Increased serum concentrations of carbamazepine were observed in clinical trials with clarithromycin. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with carbamazepine. | |||
| Antifungals: | |||||
| Itraconazole | Use With Caution | Itraconazole: Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly (see also Itraconazole under “Drugs That Affect Clarithromycin”in the table below). Clarithromycin may increase the plasma concentrations of itraconazole. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions. | |||
| Fluconazole | No Dose Adjustment | Fluconazole: [see Pharmacokinetics (12.3)] | |||
| Anti-Gout Agents: | |||||
| Colchicine (in patients with renal or hepatic impairment) | Contraindicated | Colchicine: Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. The dose of colchicine should be reduced when co-administered with clarithromycin in patients with normal renal and hepatic function[see Contraindications (4.4) and Warnings and Precautions (5.4)] . | |||
| Colchicine (in patients with normal renal and hepatic function) | Use With Caution | ||||
| Antipsychotics: | |||||
| Pimozide | Contraindicated | Pimozide: [See Contraindications (4.2)] | |||
| Quetiapine | Quetiapine: Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. Co-administration with clarithromycin could result in increased quetiapine exposure and possible quetiapine related toxicities. There have been postmarketing reports of somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation during concomitant administration. Refer to quetiapine prescribing information for recommendations on dose reduction if co-administered with CYP3A4 inhibitors such as clarithromycin. | ||||
| Lurasidone | Lurasidone: [See Contraindications (4.7)] | ||||
| Antispasmodics: | |||||
| Tolterodine (patients deficient in CYP2D6 activity) | Use With Caution | Tolterodine: The primary route of metabolism for tolterodine is via CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when co-administered with clarithromycin. | |||
| Antivirals: | |||||
| Atazanavir | Use With Caution | Atazanavir: Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction (see Atazanavir under “Drugs That Affect Clarithromycin”in the table below)[see Pharmacokinetics (12.3)] . | |||
| Saquinavir (in patients with decreased renal function) | Saquinavir: Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction (see Saquinavir under “Drugs That Affect Clarithromycin”in the table below)[see Pharmacokinetics (12.3)] . | ||||
| Ritonavir Etravirine | Ritonavir, Etravirine: (see Ritonavir and Etravirine under “Drugs That Affect Clarithromycin”in the table below)[see Pharmacokinetics (12.3)] . | ||||
| Maraviroc | Maraviroc: Clarithromycin may result in increases in maraviroc exposures by inhibition of CYP3A metabolism. See Selzentry®prescribing information for dose recommendation when given with strong CYP3A inhibitors such as clarithromycin. | ||||
| Boceprevir (in patients with normal renal function) Didanosine | No Dose Adjustment | Boceprevir: Both clarithromycin and boceprevir are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when co-administered. No dose adjustments are necessary for patients with normal renal function (see Victrelis®prescribing information). | |||
| Zidovudine | Zidovudine: Simultaneous oral administration of clarithromycin immediate-release tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Administration of clarithromycin and zidovudine should be separated by at least two hours[see Pharmacokinetics (12.3)] .The impact of co-administration of clarithromycin extended-release tablets or granules and zidovudine has not been evaluated. | ||||
| Calcium Channel Blockers: | |||||
| Verapamil | Use With Caution | Verapamil: Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil,[see Warnings and Precautions (5.4)] . | |||
| Amlodipine Diltiazem | Amlodipine, Diltiazem: [See Warnings and Precautions (5.4)] | ||||
| Nifedipine | Nifedipine: Nifedipine is a substrate for CYP3A. Clarithromycin and other macrolides are known to inhibit CYP3A. There is potential of CYP3A-mediated interaction between nifedipine and clarithromycin. Hypotension and peripheral edema were observed when clarithromycin was taken concomitantly with nifedipine[see Warnings and Precautions (5.4)] . | ||||
| Ergot Alkaloids: | |||||
| Ergotamine Dihydroergotamine | Contraindicated | Ergotamine, Dihydroergotamine: Postmarketing reports indicate that coadministration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system[see Contraindications (4.6)] . | |||
| Gastroprokinetic Agents: | |||||
| Cisapride | Contraindicated | Cisapride: [See Contraindications (4.2)] | |||
| Lipid-lowering agents: | |||||
| Lomitapide Lovastatin Simvastatin | Contraindicated | Lomitapide, Lovastatin, Simvastatin: Clarithromycin may increase the exposure of these drugs by inhibition of CYP3A metabolism, thereby increasing the risk of toxicities from these drugs [See Contraindications (4.5) and Warnings and Precautions (5.4)] Atorvastatin, Pravastatin, Fluvastatin: [See Warnings and Precautions (5.4)] | |||
| Atorvastatin Pravastatin | Use With Caution | ||||
| Fluvastatin | No Dose Adjustment | ||||
| Hypoglycemic Agents: | |||||
| Nateglinide Pioglitazone Repaglinide Rosiglitazone | Use With Caution | Nateglinide, Pioglitazone, Repaglinide, Rosiglitazone: [See Warnings and Precautions (5.4) and Adverse Reactions (6.2)] | |||
| Insulin | Insulin: [See Warnings and Precautions (5.4)and Adverse Reactions (6.2)] | ||||
| Immunosuppressants: | |||||
| Cyclosporine | Use With Caution | Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. | |||
| Tacrolimus | Tacrolimus: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with tacrolimus. | ||||
| Phosphodiesterase inhibitors: | |||||
| Sildenafil Tadalafil Vardenafil | Use With Caution | Sildenafil, Tadalafil, Vardenafil: Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors. Co-administration of these phosphodiesterase inhibitors with clarithromycin is not recommended. Increased systemic exposure of these drugs may occur with clarithromycin; reduction of dosage for phosphodiesterase inhibitors should be considered (see their respective prescribing information). | |||
| Proton Pump Inhibitors: | |||||
| Omeprazole | No Dose Adjustment | Omeprazole: The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin as a result of increased omeprazole exposures[see Pharmacokinetics (12.3)] (see also Omeprazole under “Drugs That Affect Clarithromycin”in the table below). | |||
| Xanthine Derivatives: | |||||
| Theophylline | Use With Caution | Theophylline: Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations[see Pharmacokinetics (12.3)] . Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range. | |||
| Triazolobenzodiazepines and Other Related Benzodiazepines: | |||||
| Midazolam | Use With Caution | Midazolam: When oral midazolam is co-administered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated[see Warnings and Precautions (5.4) and Pharmacokinetics (12.3)] . | |||
| Alprazolam Triazolam | Triazolam, Alprazolam: Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is co-administered with clarithromycin. There have been postmarketing reports of drug interactions and central nervous system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.In postmarketing experience, erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines. | ||||
| Temazepam Nitrazepam Lorazepam | No Dose Adjustment | Temazepam, Nitrazepam, Lorazepam: For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely. | |||
| Cytochrome P450 Inducers: | |||||
| Rifabutin | Use With Caution | Rifabutin: Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis (see Rifabutin under “Drugs That Affect Clarithromycin”in the table below). | |||
| Other Drugs Metabolized by CYP3A: | |||||
| Alfentanil Bromocriptine Cilostazol Methylprednisole Vinblastine Phenobarbital St. John’s Wort | Use With Caution | There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with alfentanil, methylprednisolone, cilostazol, bromocriptine, vinblastine, phenobarbital, and St. John’s Wort. | |||
| Other Drugs Metabolized by CYP450 Isoforms Other than CYP3A: | |||||
| Hexobarbital Phenytoin Valproate | Use With Caution | There have been postmarketing reports of interactions of clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate. | |||
Drugs that Affect Clarithromycin | |||||
Drug(s) that Affect the Pharmacokinetics of Clarithromycin | Recommendation | Comments | |||
| Antifungals: | |||||
| Itraconazole | Use With Caution | Itraconazole: Itraconazole may increase the plasma concentrations of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions (see also Itraconazole under “Drugs That Are Affected By Clarithromycin”in the table above). | |||
| Antivirals: | |||||
| Atazanavir | Use With Caution | Atazanavir: When clarithromycin is co-administered with atazanavir, the dose of clarithromycin should be decreased by 50%[see Clinical Pharmacology (12.3)] .Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to Mycobacterium avium complex. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors. | |||
| Ritonavir (in patients with decreased renal function) | Ritonavir: Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is co-administered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due toMycobacterium avium [see Pharmacokinetics (12.3)] .Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors. | ||||
| Saquinavir (in patients with decreased renal function) | Saquinavir: When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to ritonavir above)[see Pharmacokinetics (12.3)] . | ||||
| Etravirine | Etravirine: Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity againstMycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC. | ||||
| Saquinavir (in patients with normal renal function) | No Dose Adjustment | ||||
| Ritonavir (in patients with normal renal function) | |||||
| Proton Pump Inhibitors: | |||||
| Omeprazole | Use With Caution | Omeprazole: Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole[see Pharmacokinetics (12.3)] . | |||
| Miscellaneous Cytochrome P450 Inducers: | |||||
| Efavirenz Nevirapine Rifampicin Rifabutin Rifapentine | Use With Caution | Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers. Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with rifabutin (see Rifabutin under “Drugs That Are Affected By Clarithromycin”in the table above). | |||
Co-administration of clarithromycin can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy. (4, 5.2, 5.4, 7)
Clarithromycin Tablets USP, 250 mg are white to off-white oval film-coated tablets debossed with "S39" on one side and blank on the other side.
Clarithromycin Tablets USP, 500 mg are white to off-white oval film-coated tablets debossed with "S4" on one side and blank on the other side.
Clarithromycin is principally excreted via the liver and kidney. Clarithromycin may be administered without dosage adjustment to patients with hepatic impairment and normal renal function. However, in the presence of severe renal impairment with or without coexisting hepatic impairment, decreased dosage or prolonged dosing intervals may be appropriate
[see Dosage and Administration
]
.For the treatment of disseminated infection due to
Mycobacterium avium
complex (MAC), clarithromycin is recommended as the primary agents. Clarithromycin should be used in combination with other antimycobacterial drugs (e.g., ethambutol) that have shownin vitro
activity against MAC or clinical benefit in MAC treatment[see Clinical Studies (14.1)]
.Adult Patients
For treatment and prophylaxis of mycobacterial infections in adults, the recommended dose of clarithromycin is 500 mg every 12 hours.
Pediatric Patients
For treatment and prophylaxis of mycobacterial infections in pediatric patients, the recommended dose is 7.5 mg/kg every 12 hours up to 500 mg every 12 hours.
[See Use in Specific Populations (8.4)and Clinical Studies (14.1)]
.Clarithromycin therapy should continue if clinical response is observed. Clarithromycin can be discontinued when the patient is considered at low risk of disseminated infection.
For information about contraindications of other drugs indicated in combination with clarithromycin, refer to their full prescribing information (contraindications section).
We receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available